Answers are grounded in this paper and cite their sources.
The aim of this review was to identify the scientific data from 1990 onwards upon which Dietary Reference Values for riboflavin may potentially be based.A search in PubMed, Embase and Cochrane (search: up to 7 February 2014), resulted in 1,695 unique hits.Based on title and abstract, 102 articles were eligible for full text selection.Four additional articles were found by hand search.One article was not available full text.After full text screening, 66 articles were excluded, leaving 39 articles that met our inclusion criteria.The included articles were classified as randomised controlled trials (n=7), prospective cohort studies (n=15), case-cohort study (n=1), nested case-control studies (n=11) and cross-sectional studies (n=5).All included articles were extracted into evidence tables and the quality of each article was assessed.Studies were divided into three groups according to their risk of bias: high risk (n=15), moderate risk (n=23) and low risk (n=1).Eight included trials described the effect of riboflavin restriction or supplementation on biomarkers of intake and status.Sixteen articles described the association between riboflavin intakes or plasma/serum concentrations and the risk of cancer.Two articles presented evidence on the association between riboflavin intake and all-cause mortality.Six articles addressed other health outcomes (i.e.bone health n=1, cataract n=2, bladder disease n=1, premenstrual syndrome n=1, physical performance n=1).Two articles were included on maternal intake and infant health, and three articles on riboflavin concentrations in breast milk.Erythrocyte glutathione reductase activation (EGRAC) was found to be a biomarker of riboflavin intake.High riboflavin intake might lower homocysteine concentrations in subjects with the TT genotype for the MTHFR677 C→T polymorphism.The majority of the included articles on cancer risk reported no relation with riboflavin.No associations were found between riboflavin intake and bone mineral density or the risk of overactive bladder syndrome.Inconsistent results were found for the relation between riboflavin intake and the development of cataract, the risk of premenstrual syndrome, or all-cause mortality.Maternal riboflavin serum concentration during pregnancy was not associated with cleft lip occurrence in infants, but maternal riboflavin intake during pregnancy was associated with infant birth weight and length in one study after adjustments.Riboflavin concentration in breast milk reflects the dietary intake of riboflavin.
No takes yet. Share an insight, caveat, or question.
Buijssen et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: